 |
 |
The patent #7504486 you cited actually only covers 'A method of growing a crystal of a 50S ribosomal subunit from Haloarcula marismortui', i.e. the crystallisation method for the 50S subunit from this single organism (from my school Latin I deduce 'haloarcula' = 'small box of salt' and 'marismortui' = 'from the Dead Sea'!), not the crystal nor the resulting macromolecular structure. However other patents (e.g. notably #6,638,908) quoted in the article you cite do cover pretty well any untwinned crystals (i.e. in this case the crystals themselves not the crystallization method) of the large ribosomal subunit from *any* organism (again not AFAICS the structures though). Cheers -- Ian > -----Original Message----- > From: [log in to unmask] [mailto:[log in to unmask]] On > Behalf Of Paul Emsley > Sent: 08 October 2009 09:25 > To: [log in to unmask] > Subject: Re: [ccp4bb] Nobel prize for chemistry 2009 > > A Leslie wrote: > > BB members may be interested to know that the 2009 Nobel prize for > > chemistry has been awarded to Venki Ramakrishnan, Tom Steitz and Ada > > Yonath for their structural work on the bacterial ribosome. > > FYI: > > http://yalepatents.org/2009/05/26/patented-therapy-based-on-ribosome- > structure/ > > Determination and uses of the atomic structures of ribosomes and > ribosomal subunits and their ligand complexes : > http://patft1.uspto.gov/netacgi/nph- > Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum. ht > m&r=1&f=G&l=50&s1=7504486.PN.&OS=PN/7504486&RS=PN/7504486 > > Hmm. > > Paul. Disclaimer This communication is confidential and may contain privileged information intended solely for the named addressee(s). It may not be used or disclosed except for the purpose for which it has been sent. If you are not the intended recipient you must not review, use, disclose, copy, distribute or take any action in reliance upon it. If you have received this communication in error, please notify Astex Therapeutics Ltd by emailing [log in to unmask] and destroy all copies of the message and any attached documents. Astex Therapeutics Ltd monitors, controls and protects all its messaging traffic in compliance with its corporate email policy. The Company accepts no liability or responsibility for any onward transmission or use of emails and attachments having left the Astex Therapeutics domain. Unless expressly stated, opinions in this message are those of the individual sender and not of Astex Therapeutics Ltd. The recipient should check this email and any attachments for the presence of computer viruses. Astex Therapeutics Ltd accepts no liability for damage caused by any virus transmitted by this email. E-mail is susceptible to data corruption, interception, unauthorized amendment, and tampering, Astex Therapeutics Ltd only send and receive e-mails on the basis that the Company is not liable for any such alteration or any consequences thereof. Astex Therapeutics Ltd., Registered in England at 436 Cambridge Science Park, Cambridge CB4 0QA under number 3751674